Operating cash flow increased 91.0%
Operating cash flow changed +91.0% from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Operating cash flow changed +91.0% from the comparable as-filed period.
Operating income changed +29.3% from the comparable as-filed period.
Operating margin changed +1613 basis points from the comparable as-filed period.
Gross margin changed -236 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Current assets changed -35.4% from the comparable as-filed period.
Working capital changed -157.0% from the comparable as-filed period.
Current liabilities changed +100.3% from the comparable as-filed period.
Inventory changed -54.4% from the comparable as-filed period.
Inventory / revenue changed -6784 basis points from the comparable as-filed period.
Receivables / revenue changed -360 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Selling, general & administrative changed -24.0% from the comparable as-filed period.
Revenue changed +13.7% from the comparable as-filed period.
Operating cash-flow margin changed +1847 basis points from the comparable as-filed period.
Current ratio changed -67.8% from the comparable as-filed period.
Working capital / assets changed -8431 basis points from the comparable as-filed period.
Total assets changed -12.8% from the comparable as-filed period.
Shares outstanding changed +0.4% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Gross profit changed -6.8% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Trade receivables changed -2.1% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Research & development changed -3.8% from the comparable as-filed period.
R&D / revenue changed -12 basis points from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.